戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 en was greater for oral candidiasis than for vaginal candidiasis.
2  role of gamma/delta T cells in experimental vaginal candidiasis.
3 in established murine models of systemic and vaginal candidiasis.
4 e virulence of C. albicans in a rat model of vaginal candidiasis.
5  transfer completely abrogated resistance to vaginal candidiasis.
6 ers, syphilis, bacterial vaginosis (BV), and vaginal candidiasis.
7 ctive than rAls1p-N against oropharyngeal or vaginal candidiasis.
8     Gonococcal cervicitis (3.1, 1.1-9.8) and vaginal candidiasis (2.6, 1.2-5.4) were also correlated
9  significant protection against experimental vaginal candidiasis after a subcutaneous immunization wi
10 uggest a minimal role for antibodies against vaginal candidiasis, an experimental rat model has provi
11                 Bacterial vaginosis (BV) and vaginal candidiasis are prominent causes of vaginal infe
12      Clinicians have traditionally diagnosed vaginal candidiasis, bacterial vaginosis, and vaginal tr
13       Although rodent models of experimental vaginal candidiasis have been useful, several difference
14  using an estrogen-dependent murine model of vaginal candidiasis have demonstrated little to no chang
15 es in currently used rat and mouse models of vaginal candidiasis have generated a large mass of data
16                                              Vaginal candidiasis, HIV-1 culture positivity, levels of
17 pseudohyphae/hyphae is required to determine vaginal candidiasis; however, it may be not sufficient t
18                            The incidences of vaginal candidiasis (HR, 0.84; 95% CI, 0.67-1.04) and tr
19 candidiasis (OPC) compared with systemic and vaginal candidiasis in female patients with AIDS has bee
20                                              Vaginal candidiasis is common disease affecting women; h
21                                              Vaginal candidiasis is common during pregnancy.
22  Candida infections, the role of CMI against vaginal candidiasis is uncertain, both in humans and in
23 ed from clinical vaginal fluid specimens and vaginal candidiasis model systems.
24 analyzed in 137 human subjects with oral and vaginal candidiasis or carriage.
25 es and/or their limits in the acquisition of vaginal candidiasis remain unclear.
26  genetic relatedness of strains in recurrent vaginal candidiasis: strain maintenance without genetic
27              Results from an animal model of vaginal candidiasis suggest that Candida-specific cell-m
28 s with an estrogen-dependent murine model of vaginal candidiasis suggest that local cell-mediated imm
29 l specimens were studied using two models of vaginal candidiasis to determine how closely these model
30 human host, causing pathologies ranging from vaginal candidiasis to fungal sepsis.
31 ry end points were bacterial vaginosis (BV), vaginal candidiasis, trichomoniasis vaginalis (hereafter
32  immunity in protection against experimental vaginal candidiasis was evaluated through the quantifica
33                              Protection from vaginal candidiasis was transferred to naive BALB/c mice
34 cans carriers, and symptomatic patients with vaginal candidiasis were enrolled in this study.